Loading clinical trials...
Loading clinical trials...
Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Conditions
Interventions
imatinib
TruSight Oncology
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
December 19, 2023
Primary Completion Date
October 30, 2026
Completion Date
October 30, 2027
Last Updated
April 21, 2026
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions